[The factors of hereditary predisposition to lymphogranulomatosis]. / Faktory nasledstvennoi predraspolozhennosti k limfogranulematozu.

AIM: To determine genetic factors of predisposition marked HLA with reference to serological and molecular characteristics. MATERIALS AND METHODS: Four groups of patients were included in the study: 51 patients with lymphogranulomatosis (LGM), 33 healthy relatives of these patients, 37 patients with chronic myeloid leukemia (CML), 24 healthy relatives of these CML patients. 224 donors served control. HLA-antigens were identified with the lymphocytoxic test and PSR-MSSR. Results of typing of class II antigens were taken into consideration in coincidence of serological and DNA typing. The significance of the differences was estimated according to the chi-square criterion. RESULTS: Differences in frequency of distribution of HLA-antigens (subloci A and B) were not found. Antigen CW7 was present in 70, DR5 in 60, DR6 in 50% of LGM patients. This frequency was much higher than in control groups. Carriers of CW7 are at 7 times higher risk to develop LGM. Among LGM patients the number of homozygous individuals is higher than in healthy ones (50 and 15.6%) while the number of individuals with a complete set of HLA-A.B antigens is significantly less. CONCLUSION: Genetic predisposition to LGM is predetermined by HLA antigens CW7, DR5, DR6. Genes HLA-DR1 and HLA-DR7 protect carriers from factors provoking LGM. Common HLA genes in the parents predispose their children to LGM. Insufficiency of the phenotype is a factor predisposing to LGM.

[HLA class I and II antigens and diffuse toxic goiter]. / Antigeny HLA I i II klassa i diffuznyi toksicheskii zob.

The incidence rate of HLA class I and II antigens has been studied in 168 and 82 patients with diffuse toxic goiter, respectively. Positive association is found for HLA antigens A2, A3, A28, B8, B15, B17, Cw4, DR5; negative one with antigens A24, Bw4, Bw6, Cw1, Cw2, Cw3, Cw5, DR9. Prevalence of antigens B15, B17, Cw4, DR5 is associated with thyrotoxicosis severity, A2 with recurrent toxic goiter. Antigen B8 plays the role of an immunogenetic marker of endocrine ophthalmopathy.

[The importance of immunogenetic studies in Itsenko-Cushing disease combined with other endocrine diseases]. / Znachimost' immunogeneticheskikh issledovanii pri bolezni Itsenko--Kushinga v sochetanii ee s drugimi éndokrinnymi zabolevaniiami.

Ninety-seven patients suffering from Itsenko [correction of Icenko]-Cushing disease were examined. Analysis was made first of all of the clinical and laboratory signs pointing to the presence of other endocrine diseases to distinguish two groups of patients. The first group included subjects who did not manifest any concomitant diseases. The number of men and women was the same. The second group was made up of patients with associated Itsenko [correction of Icenko]-Cushing disease and other endocrine diseases. In this particular group, women were predominant. The first group patients demonstrated the predominance of the DR7 incidence, the second group that of the DR5. The method of estimating HLA associations identified is proposed. It allows distinguishing specific and nonspecific associations. In Itsenko [correction of Icenko]-Cushing disease, DR7 association is specific, whereas B8 and DR5 associations are unspecific. A specific polyendocrine autoimmune syndrome associated with Itsenko [correction of Icenko]-Cushing disease was revealed. A concept of the pathogenesis of Itsenko [correction of Icenko]-Cushing disease is advanced.

[Association of I and II class HLA antigens with Cushing's syndrome]. / Assotsiatsiia HLA-antigenov I i II klassov s bolezn'iu Itsenko- Kushinga.

Incidence of class I and II HLA antigens was studied in 69 patients suffering from Icenko--Cushing syndrome. Positive association was reported for antigens DRw53, DQw3, DR4, DR5, negative for antigen DR2. Antigen combinations DR5, DR7 and DR4, DR5 proved more prevalent. The risk to develop the disease rose 2-3-fold in case of HLA-DR5 phenotype occurrence with antigen DR4 or DR7. Association with DRw53 and DQw3 antigens showing wide specificity seemed most significant.

[The creation of an all-Union registry of typed donors--the first stage towards bone marrow transplantation from an unrelated donor]. / Sozdanie vsesoiuznogo registra tipirovannykh donorov--pervyi étap k transplantatsii kostnogo mozga ot nerodstvennogo donora.

The changes in tactic approaches may be recorded in clinical transplantation of the bone marrow (TBM). The countries of Europe and America realize TBM from the HLA-compatible unrelated donor. The first stage in such TBM is the establishment of the All-Union Register of typified donors which includes about 8,000 persons and is the member of the World Donor International Association. The authors describe the scientific and organizational principles of the work in the international regime; provide the ethnic and genogeographic characteristics of the All-Union Register. Give brief data on the activity of the All-Union Register during April 15 -- December 1, 1990.

[The HLA system and Itsenko-Cushing disease]. / Sistema HLA i bolezn' Itsenko-Kushinga.

The determination of HLA antigens in 54 patients with Icenko-Cushing's disease demonstrated the high rate of AIO antigens (50.7%), B8 (27.3%) and B27 (26.2%) antigens. In the control group, the rate of the same antigens amounted to 17.8, 16.3 and 7.4%, respectively. Specific features were also revealed in the rate of individual HLA haplotypes. The rate of A X IO, B8; A X IO, B27 haplotypes occurring relatively rarely in normal subjects was high in patients with Icenko-Cushing's disease. The high rate of AIO, B8 and B27 antigens may attest to the high risk of the development of Icenko-Cushing's disease in subjects carrying these antigens.

[Production of monospecific immunoglobulin against human leukocyte interferon]. / Poluchenie monospetsificheskogo immunoglobulina protiv chelovecheskogo leikotsitarnogo interferona.

Donkeys were regularly, at seven-day intervals, immunized subcutaneously with human leukocyte interferon (IF) with the activity of 1.6 X 103 U/10 ml. IF-neutralizing antibodies in the titre of 1:128-1:256 were detected in the animals' sera after 38-40 injections. As a result of continuing injections the titre of these antibodies increased considerably. The antibodies to the components of the system in which the IF was obtained were revealed in parallel. Donkey antiinterferon plasma was prepared by plasmapheresis and antiinterferon immunoglobulin (AIFIG) was released from the plasma by centrifugation using ammonium sulphate at 50% saturation. Contamination antibodies were removed from AIFIG by affin chromatography on combined immunosorbent.

Lymphocytes' cytotoxicity towards cells of human lymphoblastoid lines in patients with rheumatoid arthritis and systemic lupus erythematosus.

A research study and discussion of antiinterferon immunoglobulin in the treatment of rheumatoid arthritis and systemic lupus erythematosus, and its possible value in the treatment of allergic diseases, autoimmune diseases and other diseases where it is presumed there may be an autoimmune genesis.

[Effect of interferon on the immune response of mice to immunization with the cells of transplantable leukemias and sarkomas]. / Vliianie interferona na immunnyi otvet myshei pri immunizatsii kletkami perevivaemykh leikozov i sarkom.

The treatment of cells L-1210 and MX-11 in vitro with interferon, prior to their injection to mice, caused an enhancement of specific humoral response and cytotoxic action of immune lymphocytes to Cr51 labelled target cells. The injecting of mice with allogeneic interferon-containing serum against the background of immunization with L-1210 cells produces an enhancing effect upon the immune response. Much more marked enhancing effect was observed when using syngeneic interferon-containing serum. Short-term treatment of lymphocytes, being immune to L-1210 cells, with interferon in vitro leads to the increase of their specific cytotoxicity to Cr51 labelled cells. Pre-treatment of leukemic cells with interferon would enhance their sensitivity to specific antibodies. It is suggested to use an active immunization of acute leukemia patients with allogeneic leukemic cells pre-incubated in interferon in combination with the injection of interferon-containing donor plasma.

[Stimulation of humoral immunity to surface antigens of leukemia cells using interferon-containing sera]. / Stimuliatsiia gumoral'nogo immuniteta k poverkhostnym antigenam leikoznykh kletok s pomoshch'iu interferonsoderzhashchei syvorotki

C57BL/6 mice were immunized once with leukemic cells L 1210; (CBAXC57BL/6) F1 mice were immunized once with leukemic cells L 1210 and P-388. These animals were injected intraperitoneally for 8 days (including the day of immunization) with 0.4 ml each of allogeneic or syngeneic interferon-containing serum; as to control animals, they received the same amount of normal serum from the intact mice. The interferon-containing serum was obtained from the (CBAXC57BL/6) F1 mice 24 hours after the intraperitoneal injection of 2 mg of tilorone hydrochloride. Some of the samples of the interferon-containing serum were subjected to the 48-hour dialysis against the physiological saline. The interferon titer in the serum was 512-1500 units/ml. The sera from mice were tested in the microcytotoxic test against leukemic cells 9-10 days after the immunization. A distinct stimulation of the cytotoxic activity of the sera from mice given the interferon-containing serum was observed. Syngeneic interferon-containing serum caused a more marked immunity-stimulating effect than allogeneic serum.